MedTrace Logo

Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma

NCT00360945 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving cisplatin together with temozolomide works in treating young patients with malignant glioma.

Conditions

Interventions

DRUG

cisplatin

DRUG

temozolomide

GENETIC

fluorescence in situ hybridization

GENETIC

loss of heterozygosity analysis

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

RADIATION

radiation therapy

Sponsors & Collaborators

  • Children's Cancer and Leukaemia Group

    lead OTHER

Principal Investigators

  • Steve Lowis, MD, PhD, BA, MRCP, MRCPCH · Bristol Royal Hospital for Children

  • Jacques Grill, MD, PhD · Gustave Roussy, Cancer Campus, Grand Paris

  • Anthony Michalski, MD · Great Ormond Street Hospital for Children NHS Foundation Trust

  • David A. Walker · Queen's Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
4 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30

Countries

  • France
  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00360945 on ClinicalTrials.gov